BIOLINERX LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.7 ILa | -2.34% |
|
-6.18% | -56.28% |
| Sales 2024 * | 14.36M 5.4B | Sales 2025 * | 27.77M 10.44B | Capitalization | 52.76M 19.83B |
|---|---|---|---|---|---|
| Net income 2024 * | -47M -17.67B | Net income 2025 * | -36M -13.53B | EV / Sales 2024 * | 3.67 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.9 x |
| P/E ratio 2024 * |
-2.2
x | P/E ratio 2025 * |
-
| Employees | 79 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioLineRx Ltd.
More press releases
| 1 day | -2.34% | ||
| 1 week | -6.18% | ||
| Current month | -40.57% | ||
| 1 month | -42.21% | ||
| 3 months | -52.82% | ||
| 6 months | -56.85% | ||
| Current year | -56.28% |
1 week
16.50
19.00
1 month
16.5033.50
Current year
16.5040.60
1 year
16.5070.00
3 years
13.40136.00
5 years
13.40162.70
10 years
13.401 059.00
| Managers | Title | Age | Since |
|---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 62 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Michael Anghel
BRD | Director/Board Member | 85 | 10-08-31 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 16.7 | -2.34% | 1,098,013 |
| 24-04-17 | 17.1 | +0.59% | 2,295,728 |
| 24-04-16 | 17 | -5.56% | 2,308,134 |
| 24-04-15 | 18 | -0.55% | 1,007,013 |
| 24-04-14 | 18.1 | +1.69% | 1,301,451 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 18, 2024 at 10:24 am EDT
More quotes
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.28% | 52.76M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- BLRX Stock
